Clinical Trials Browser

Phase 1/2 × Completed × Has announcements × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 5 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02500407 2025-09-12

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

713 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03548207 2025-07-30

CARTITUDE-1

Phase 1/2 Completed

126 enrolled 36 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Phase 1/2 Completed

336 enrolled 48 charts 2 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03037385 2025-05-31

ARROW

Phase 1/2 Completed

590 enrolled 58 charts 8 FDA

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Phase 1/2 Completed

407 enrolled 45 charts 2 FDA

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

1,163 enrolled 33 charts 2 FDA

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02614066 2024-11-19

ZUMA-3

Phase 1/2 Completed

125 enrolled 27 charts 2 FDA

Recurrence

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase 1/2 Completed

345 enrolled 120 charts 2 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Phase 1/2 Completed

130 enrolled 34 charts 3 FDA

Myeloid

Myelodysplastic Syndromes

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

138 enrolled 23 charts 3 FDA

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase 1/2 Completed

400 enrolled 22 charts 3 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 2 FDA

Tumor-Agnostic

Neoplasms

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

331 enrolled 81 charts 2 FDA

Lymphoid

Lymphoma

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase 1/2 Completed

385 enrolled 29 charts 4 FDA

Lymphoid

B-cell Malignancies

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 3 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Phase 1/2 Completed

139 enrolled 42 charts 2 FDA

CNSMyeloid

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase 1/2 Completed

122 enrolled 24 charts 4 FDA

CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT02195869 2019-07-11

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Phase 1/2 Completed

45 enrolled 13 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Phase 1/2 Completed

22 enrolled 13 charts 2 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

Clinical Trials

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

CheckMate040

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

CARTITUDE-1

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

ARROW

A Study of TAS-120 in Patients With Advanced Solid Tumors

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

ZUMA-3

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects